2023
Ritlecitinib (PF-06651600), an oral JAK3/TEC inhibitor, shows efficacy in patients with active nonsegmental vitiligo and either a lighter or darker Fitzpatrick skin type: results from a phase 2b, randomized, dose-ranging study with an extension period
Peeva E, Yamaguchi Y, King B, Han G, Cox L, Banerjee A, Picardo M, Bae J, Sloan A, Sinclair R, Ezzedine K. Ritlecitinib (PF-06651600), an oral JAK3/TEC inhibitor, shows efficacy in patients with active nonsegmental vitiligo and either a lighter or darker Fitzpatrick skin type: results from a phase 2b, randomized, dose-ranging study with an extension period. British Journal Of Dermatology 2023, 188: ljac106.004. DOI: 10.1093/bjd/ljac106.004.Peer-Reviewed Original ResearchTreatment-emergent adverse eventsDose-ranging periodNonsegmental vitiligoLoading doseFitzpatrick skin typeIncidence of treatment-emergent adverse eventsFacial Vitiligo Area Scoring IndexTreatment-emergent adverse event incidenceLow dosesDarker Fitzpatrick skin typesVitiligo Area Scoring IndexDaily loading dosesRandomized to placeboDose-ranging studyPhase 2b studyPhase 2b trialLow-dose groupCytokine IL-15Skin typePlateau of effectivenessSafety endpointsIL-15IFN-gAdverse eventsVitiligo patients
2022
Efficacy and safety of oral ritlecitinib for the treatment of active nonsegmental vitiligo: A randomized phase 2b clinical trial
Ezzedine K, Peeva E, Yamaguchi Y, Cox L, Banerjee A, Han G, Hamzavi I, Ganesan A, Picardo M, Thaçi D, Harris J, Bae J, Tsukamoto K, Sinclair R, Pandya A, Sloan A, Yu D, Gandhi K, Vincent M, King B. Efficacy and safety of oral ritlecitinib for the treatment of active nonsegmental vitiligo: A randomized phase 2b clinical trial. Journal Of The American Academy Of Dermatology 2022, 88: 395-403. PMID: 36370907, DOI: 10.1016/j.jaad.2022.11.005.Peer-Reviewed Original ResearchConceptsNonsegmental vitiligoLoading doseScoring IndexPercent changePhase 2b clinical trialExtension periodPhase 2b trialPrimary efficacy endpointSerious adverse eventsChronic autoimmune disorderDose-dependent trendEfficacy endpointAdverse eventsWeek 24Autoimmune disordersClinical trialsStable vitiligoPatientsVitiligoSignificant differencesTreatmentDoseBaselineTrialsWeeks